NCT06387121View on ClinicalTrials.gov

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2028

Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
DRUG

Vincristine

Anti-tumor alkaloids

DRUG

Cyclophosphamide

Alkylating agent

DRUG

Dexamethasone

Glucocorticoids

DRUG

Venetoclax

Selective inhibitor of B-cell lymphoma 2 (Bcl-2)

DRUG

Inotuzumab ozogamicin

A humanized monoclonal antibody-drug conjugate targeting CD22

DRUG

Blinatumomab

Bi-specific anti-CD19/CD3 antibodies

DRUG

6-mercaptopurine

Cell cycle-specific antitumor drug

DRUG

Methotrexate

Antifolate antineoplastic drug

DRUG

Cytarabine

Pyrimidine antimetabolites

DRUG

Prednisone

Glucocorticoids

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER